Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Part of paid clinical trials in New York, New York.

Sponsor
Shambavi Richard
Study ID
NCT07727668
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Iberdomide — DRUG
    1.0mg iberdomide capsules administered orally, daily on days 1-21 of a 28-day cycle
  • CAR-T Leukapheresis — PROCEDURE
    A procedure in which blood is collected and white blood cells (including T cells) are separated and collected. The remaining blood components are returned to the participant. The collected T cells will be used to manufacture the CAR-T cell therapy.
  • CAR-T Infusion — PROCEDURE
    Participants will receive an intravenous infusion of standard-of-care CAR-T therapy manufactured from the participant's previously collected cells

Study Details

This feasibility trial studies the efficacy of administering iberdomide (CC-220) as a priming agent prior to leukapheresis in patients with relapsed/refractory multiple myeloma (RRMM) who are already planned for standard-of-care CAR-T therapy. Giving iberdomide before CAR-T may improve T cell fitness which may improve CAR-T expansion kinetics and response after infusion.

Key Dates

First listed
Jul 27, 2026
Start date
Jul 31, 2026
Status verified
Jul 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2031

Study Design

Enrollment
22 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Patients with RRMM
    Patients with RRMM who are already planned for standard-of-care CAR-T therapy. Study participants will be planned for one cycle (28 days) of iberdomide therapy (1.0mg daily on days 1-21 of a 28-day cycle), followed by CAR-T leukapheresis. Patients will then proceed with CAR-T infusion per standard of care, with additional lab monitoring for T cell phenotyping and CAR-T expansion kinetics.

Primary Outcome Measure

Proportion of patients with T cell effector memory (TEM) expansion following iberdomide priming. [ Time Frame: On the day of leukapheresis, after completing iberdomide therapy on Day 29 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Vikram Madan
[email protected]
(646) 745-6092
Rashmi Unawane
[email protected]
212-824-2385
Shambavi Richard (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

Nationwide
Multiple myeloma trialsOncology trialsBlood cancer trials
By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Icahn School of Medicine at Mount Sinai· New York, NY

Related Studies